Citadel Advisors’s Audentes Therapeutics, Inc BOLD Stock Holding History

Citadel Advisors’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,400	Closed	-$622K	–	10602
2019 Q4	$622K	Buy	10,400 +1,900	+22%	+$71.3K	﹤0.01%	6460
2019 Q3	$239K	Sell	8,500 -3,400	-29%	-$116K	﹤0.01%	7905
2019 Q2	$451K	Buy	11,900 +5,200	+78%	+$200K	﹤0.01%	6984
2019 Q1	$261K	Buy	+6,700	New	+$192K	﹤0.01%	7826
2018 Q4	–	Sell	-6,200	Closed	-$245K	–	10126
2018 Q3	$245K	Sell	6,200 -5,000	-45%	-$186K	﹤0.01%	7907
2018 Q2	$428K	Sell	11,200 -4,200	-27%	-$156K	﹤0.01%	6633
2018 Q1	$463K	Buy	+15,400	New	+$521K	﹤0.01%	6009

Citadel Advisors's BOLD Position: Q4 2019 in Review

Citadel Advisors sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2019, closing a stake of 1,017,783 shares — an estimated $38.2M sold.

Citadel Advisors first reported a position in BOLD in Q1 2017 and held it in 10 quarters. The position peaked at $28.6M in Q3 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.

Citadel Advisors reported no remaining Audentes Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
Citadel Advisors sold 1,017,783 Audentes Therapeutics, Inc shares in Q4 2019, an estimated $38.2M.
Citadel Advisors first reported a position in Audentes Therapeutics, Inc in Q1 2017 and held it in 10 quarters.
Citadel Advisors's Audentes Therapeutics, Inc position peaked at $28.6M in Q3 2019.
188 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.